The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

StocksMediumUpdated×4•Originally published 30 April 2026•Updated 1 May 2026•

1 min read

Mixed Pharma Results and Record Bookings for Trane Technologies in Q1

Key Facts

1Merck & Co reported a first-quarter loss due to an acquisition-related charge involving Cidara.

2Product sales increased by 5% driven by cancer and respiratory drugs.

The pharmaceutical sector showed mixed results as Merck & Co's sales growth was driven by its blockbuster drug Keytruda, leading the company to tighten its 2026 sales outlook. Meanwhile, Bristol Myers Squibb beat estimates on the back of its new portfolio, and Moderna reported an increase in first-quarter revenue driven by international Covid-19 vaccine sales, despite reporting a net financial loss. In the industrial sector, Trane Technologies reported record bookings of $10.7 billion, representing a 24% year-over-year increase. Due to this robust demand, Trane raised its financial guidance for 2026. These updates highlight sustained commercial momentum across both healthcare and climate innovation sectors. Analysts suggest that the underlying operational strength and record backlogs support a positive long-term trajectory for these industry leaders.

about 1 month ago

Version History

Version 4about 1 month ago

What changed: Added Moderna's Q1 financial results, noting the increase in international vaccine revenue alongside a net loss.

Version 3about 1 month ago

What changed: Added specific drivers for Merck's growth (Keytruda) and introduced new earnings data for Trane Technologies, including record bookings and updated 2026 outlook.

Version 2about 1 month ago

What changed: The story was updated to reflect that Merck exceeded market expectations, reported a smaller-than-expected loss, and raised its full-year financial guidance.

Version 1about 1 month ago

What changed: The story was updated to include positive quarterly results from Bristol Myers Squibb, providing a broader perspective on pharmaceutical sector performance.